Download PDF
CC BY-NC-ND 4.0 · World J Nucl Med 2019; 18(04): 424-427
DOI: 10.4103/wjnm.WJNM_50_18
Case Report

Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted 18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern

Yafu Yin
1   The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
2   Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, China
,
Channing J. Paller
3   Department of Oncology, The Sidney Kimmell Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
,
Martin G. Pomper
1   The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
3   Department of Oncology, The Sidney Kimmell Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
4   Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
,
Kenneth J. Pienta
3   Department of Oncology, The Sidney Kimmell Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
4   Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
,
Michael A. Gorin
1   The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
3   Department of Oncology, The Sidney Kimmell Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
4   Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
,
Steven P. Rowe
1   The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA
4   Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

New radiotracers for positron emission tomography imaging that target prostate-specific membrane antigen (PSMA) have emerged as important clinical tools for imaging prostate cancer (PCa). PSMA-targeted radiotracers have demonstrated high sensitivity and high specificity for detecting sites of PCa and are demonstrably superior to conventional imaging modalities such as computed tomography and bone scan. Vas deferens invasion is a rarely encountered poor prognostic feature of PCa. In this case report, we describe a novel pattern of radiotracer uptake in a patient with PCa imaged with PSMA-targeted 18F-DCFPyL positron emission tomography/computed tomography that is consistent with diffuse vas deferens involvement.

Keywords

18F-DCFPyL - positron emission tomography/computed tomography - prostate cancer - prostate-specific membrane - vas deferens

Financial support and sponsorship

We gratefully acknowledge funding from Progenics Pharmaceuticals Inc., The Prostate Cancer Foundation Young Investigator Award, and National Institutes of Health grants CA134675 and CA183031.




Publication History

Received: 09 May 2018

Accepted: 30 May 2018

Article published online:
22 April 2022

© 2019. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Jang WS, Yoon CY, Kim KH, Kang YJ, Shin SJ, Cho NH, et al. Prognostic significance of vas deferens invasion after radical prostatectomy in patients with pathological stage T3b prostate cancer. Ann Surg Oncol 2017;24:1143-9.
  • 2 Rowe SP, Mana-Ay M, Javadi MS, Szabo Z, Leal JP, Pomper MG, et al. PSMA-based detection of prostate cancer bone lesions with18 F-DCFPyL PET/CT: A Sensitive alternative to (99 m) Tc-MDP bone scan and Na18 F PET/CT? Clin Genitourin Cancer 2016;14:e115-8.
  • 3 Rowe SP, Macura KJ, Mena E, Blackford AL, Nadal R, Antonarakis ES, et al. PSMA-based [(18) F] DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer. Mol Imaging Biol 2016;18:411-9.
  • 4 Rowe SP, Gorin MA, Chu LC, Pienta KJ, Pomper MG, Ross AE, et al. An unusual case of penile prostate cancer uncovered by multiparametric MRI and PSMA-targeted 18F-DCFPyL PET/CT. Clin Nucl Med 2017;42:e441-3.
  • 5 Polverari G, Ceci F, Graziani T, Cozzarini C, Castellucci P, Fanti S, et al. Arare case of epididymal metastasis after radical prostatectomy detected by 68Ga-PSMA PET/CT. Clin Genitourin Cancer 2017;15:e525-7.
  • 6 Phillips RM, Gorin MA, Rowe SP, Pomper MG, Pienta KJ, Ross AE, et al. Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT. Urol Case Rep 2018;16:86-8.
  • 7 Rowe SP, Gorin MA, Hammers HJ, Som Javadi M, Hawasli H, Szabo Z, et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted18 F-DCFPyL PET/CT. Ann Nucl Med 2015;29:877-82.
  • 8 Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: A systematic review and meta-analysis. Eur Urol 2016;70:926-37.
  • 9 Gorin MA, Rowe SP, Patel HD, Vidal I, Mana-Ay M, Javadi MS, et al. Prostate specific membrane antigen targeted 18F-DCFPyL positron emission tomography/computerized tomography for the preoperative staging of high risk prostate cancer: Results of a prospective, phase II, single center study. J Urol 2018;199:126-32.
  • 10 Sheikhbahaei S, Afshar-Oromieh A, Eiber M, Solnes LB, Javadi MS, Ross AE, et al. Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging. Eur J Nucl Med Mol Imaging 2017;44:2117-36.